Share on StockTwits

IGI Laboratories (NYSE:IG) CEO Jason Grenfell-Gardner sold 66,828 shares of the company’s stock in a transaction dated Monday, August 4th. The shares were sold at an average price of $5.85, for a total transaction of $390,943.80. Following the completion of the transaction, the chief executive officer now directly owns 271,672 shares of the company’s stock, valued at approximately $1,589,281. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

IGI Laboratories (NYSE:IG) traded up 1.36% on Wednesday, hitting $5.98. 919,096 shares of the company’s stock traded hands. IGI Laboratories has a one year low of $1.45 and a one year high of $6.14. The stock’s 50-day moving average is $5.55 and its 200-day moving average is $4.8. The company’s market cap is $281.8 million.

IGI Laboratories (NYSE:IG) last released its earnings data on Thursday, July 24th. The company reported ($0.01) earnings per share (EPS) for the quarter. Analysts expect that IGI Laboratories will post $0.01 EPS for the current fiscal year.

Separately, analysts at Zacks downgraded shares of IGI Laboratories from a “neutral” rating to an “underperform” rating in a research note on Monday, July 28th. They now have a $5.00 price target on the stock.

IGI Laboratories, Inc (NYSE:IG) develops, manufactures, fills and packs topical semi-solid and liquid products for cosmetic, cosmeceutical and pharmaceutical customers.

Receive News & Ratings for IGI Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGI Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.